ArticleVox sanguinis2025
Stable SARS-CoV-2 antibody levels and functionality in serum and COVID-19 convalescent plasma after long-term storage.
Article in Vox sanguinis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
BACKGROUND AND
objectivesThe coronavirus disease 2019 (COVID-19) pandemic necessitated various therapeutic approaches, including convalescent plasma (CP) administration. The administration timing of COVID-19 CP (CCP), antibody specificity and quantity were identified as crucial factors for therapeutic success. Currently, antibody durability and storage time are still under debate. The aim of this study was to evaluate the stability and in vitro functionality of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) antibodies in human plasma and serum after long-term storage, to provide a framework for generally applicable rules regarding the long-term storage of CCP. MATERIALS AND
methodsSerum and plasma samples of CCP donations were investigated at the time of donation and after 2 and 3 years' storage at less than -30°C using (electro)chemiluminescence immunoassays and enzyme-linked immunosorbent assays, with the plasma undergoing multiple freezing and thawing.
resultsOur data reveal robust levels of SARS-CoV-2 antibodies after long-term storage. Furthermore, our findings also indicate that multiple freezing and thawing cycles do not affect the antibody levels or their neutralizing capability.
conclusionAs antibody stability and in vitro functionality are maintained over extended periods, even after repeated freezing and thawing, our findings support long-term storage of CCP, particularly benefiting vulnerable populations such as immunocompromised individuals. By now, donors have likely encountered various SARS-CoV-2 variants and vaccine-acquired antibodies. This antibody mix present in CCP is suggested to protect even against new variants. Our data indicate that current regulations for the storage of CCP can be extended and that CCPs could be used for therapeutic purposes after long-term storage without significant loss of antibody quantity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.